FindTrial
Sign In

CYTOKINES(INFLAMMATORY MARKERS) IN SEVERE AND MODERATE COVID 19 PATIENTS AND ITS RELATION WITH THE OUTCOMES

IL-6,TNF ALPHA,INF GAMMA AND IL-1 BETA LEVELS IN SEVERE AND MODERATE COVID 19 PATIENTS AND ITS RELATION WITH OUTCOMES

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/12/030082
Enrollment
50
Registered
2020-12-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B998- Other infectious disease

Interventions

None listed

Sponsors

PAVULURI KRISHNA SWATHI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: PATIENTS MORE THAN 18YEARS OF AGE AND WHO ARE RT PCR FOR SARS COV 2 PROVEN ADMITTED TO THE COVID WARD AND WHO ARE RADIOLOGICALLY MODERATE AND SEVERE COVID 19.

Exclusion criteria

Exclusion criteria: AUTOIMMUNE DISORDERS PATIENTS ON BIOLOGIC DMARDS PREGNANCY OTHER BACTERIAL AND VIRAL INFECTIONS

Design outcomes

Primary

MeasureTime frame
4 CYTOKINES(IL-6,TNF ALFA,INF GAMMA AND IL-1 B) ON DAY 1 AND DAY 10,MORTALITY OR MORBIDITY.Timepoint: DAY 1 AND DAY 10—

Secondary

MeasureTime frame
WHETHER IT IS MORBIDITY OR MORTALITYTimepoint: DAY 1 AND DAY 10 OF MENTIONED CYTOKINES—

Countries

India

Contacts

Public ContactPAVULURI KRISHNA SWATHI

SRIHER

senthilresearch2020@gmail.com9381049376

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026